Texas § 549.0309 GENERAL POWERS AND DUTIES OF BOARD.

Texas Statutes

§ 549.0309 — GENERAL POWERS AND DUTIES OF BOARD.

Texas § 549.0309

Code GVGovernment Code

This text of Texas § 549.0309 (GENERAL POWERS AND DUTIES OF BOARD.) is published on Counsel Stack Legal Research, covering Texas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

Tex. Government Code Code Ann. § 549.0309 (2026).

Text

Sec. 549.0309. GENERAL POWERS AND DUTIES OF BOARD.

(a)In addition to performing any other duties required by federal law, the board shall:

(1)develop and submit to the commission recommendations for the preferred drug lists the commission adopts under Subchapter E;

(2)suggest to the commission restrictions or clinical edits on prescription drugs;

(3)recommend to the commission educational interventions for Medicaid providers;

(4)review drug utilization across Medicaid; and

(5)perform other duties that may be specified by law and otherwise make recommendations to the commission.

(b)In developing recommendations for the preferred drug lists, the board shall consider the clinical efficacy, safety, and cost-effectiveness of, and any program benefit associated with, a product.

(c)To the

Free access — add to your briefcase to read the full text and ask questions with AI

Sec. 549.0309. GENERAL POWERS AND DUTIES OF BOARD. (a) In addition to performing any other duties required by federal law, the board shall:
(1) develop and submit to the commission recommendations for the preferred drug lists the commission adopts under Subchapter E;
(2) suggest to the commission restrictions or clinical edits on prescription drugs;
(3) recommend to the commission educational interventions for Medicaid providers;
(4) review drug utilization across Medicaid; and
(5) perform other duties that may be specified by law and otherwise make recommendations to the commission.
(b) In developing recommendations for the preferred drug lists, the board shall consider the clinical efficacy, safety, and cost-effectiveness of, and any program benefit associated with, a product.
(c) To the extent feasible, the board:
(1) shall review all drug classes included in the preferred drug lists at least once every 12 months; and
(2) may recommend inclusions in and exclusions from the lists to ensure that the lists provide for a range of clinically effective, safe, cost-effective, and medically appropriate drug therapies for the diverse segments of the Medicaid population, children receiving health benefits coverage under the child health plan program, and any other affected individuals.